We believe that the strengths of our model are its simplicity, use of physiologic mechanisms, ability to describe brain volume and NfL data from healthy controls and HD subjects, and the incorporation of CSF flow measurements reported in populations that are similar to those in the HD-CSF study. The gene discussed is NEFL; the disease is Huntington disease.